- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 7 - Barriers When Managing Diabetes
During this segment, Peter Salgo, MD, notes that the success rates in the management of type 2 diabetes mellitus (T2DM) are mixed: the percentage of patients achieving the target glycated hemoglobin (A1C) of less than 7% has declined, but fewer patients have an A1C greater than 9%. To help get more patients to goal, Dr Salgo leads a discussion about the variables that physicians should consider when selecting therapy for patients with T2DM.
Kari Uusinarkaus, MD, FAAFP, FNLA, explains that as new agents emerge, physicians need to consider the risks and benefits of therapy on an individualized basis. Dr Uusinarkaus states that the costs of treatment affect treatment decisions, and in practice, less expensive sulfonylureas are often used as a first-line option.
Yehuda Handelsman, MD, FACP, FACE, FNLA, notes that the use of less expensive options such as sulfonylureas is an issue, due to their lack of effectiveness over the long term.
Jeffrey D. Dunn, PharmD, MBA, discusses the challenges that affect the costs and coverage of emerging agents. Dr Dunn explains that formularies are population-centric and are based on a comparison of efficacy, safety, and cost across drugs.
Maria Lopes, MD, MS, adds that clinical inertia is a challenge. Patients are still not at A1C goal despite being treated with multiple agents. Dr Lopes suggests that a more algorithmic approach may help get patients to goal more quickly, while taking into account risks versus benefits and treatment individualization.
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
